Voglibose

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.[1]

Voglibose

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A10BF03 (WHO)
Identifiers
IUPAC name (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
CAS Number	83480-29-9 Y
PubChem CID	444020
DrugBank	DB04878 Y
ChemSpider	392046 Y
UNII	S77P977AG8
KEGG	D01665 Y
ChEMBL	ChEMBL476960 Y
CompTox Dashboard (EPA)	DTXSID2021442
Chemical and physical data
Formula	C10H21NO7
Molar mass	267.28 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O
InChI InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 Y Key:FZNCGRZWXLXZSZ-CIQUZCHMSA-N Y
(verify)

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.